6505--radiopharmaceuticals for robert J. Dole VAMC, wichita, KS five year IDIQ

The Department of Veterans Affairs Veterans Integrated Service Network 15 seeks radiopharmaceuticals and delivery services for the Nuclear Medicine Department at Robert J. Dole VA Medical Center in Wichita, Kansas, via a five-year IDIQ contract on firm fixed-price basis, with proposals due May 27, 2026 at 7:00 a.m. Central Time and questions due May 6 at 10:00 a.m. Central Time. An amendment issued May 7 adds FAR clause 52.222-90 regarding diversity, equity, and inclusion compliance; a second amendment issued May 14 extends the proposal deadline from the original May 15 date to May 27 with no substantive changes to requirements.

The procurement carries no small business set-aside and is unrestricted. Performance runs five twelve-month periods from August 1, 2026 through July 31, 2031. The contractor must be located within fifty miles of the medical center or capable of delivering emergent orders within one hour, 24 hours daily, seven days weekly. Required products include Tc-99m radiopharmaceuticals (Tetrofosmin, NaTcO4, Medronate, Sulfur Colloid, Macro Aggregated Albumin, Mebrofenin, Sestamibi, Mertiatide, FSC), I-123 compounds, In-111 products, Xe-133 xenon gas, and Thallium-201, with estimated quantities ranging from single units to 2,000 units annually by product. Pricing includes separate line items for scheduled weekday deliveries (up to five per occurrence), weekend and holiday deliveries, after-hours callouts, stat deliveries, and specialized White Blood Cell after-hours services.

The contractor must hold current NRC/Agreement State licenses, FDA registration, and employ board-certified radiopharmacists or nuclear medicine technologists. Evaluation weighs price, technical capability, and past performance equally. Proposals must include completed SF-1449, detailed price schedule across all five performance periods, technical narrative demonstrating scope of work compliance and emergency response capability, proof of required licenses and certifications, and at least three past performance references for similar radiopharmaceutical services within the last three years.